Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 2002 Oct;110(Suppl 5):779–782. doi: 10.1289/ehp.02110s5779

Chiral discrimination in platinum anticancer drugs.

Michele Benedetti 1, Jaroslav Malina 1, Jana Kasparkova 1, Viktor Brabec 1, Giovanni Natile 1
PMCID: PMC1241244  PMID: 12426131

Abstract

In this article we review the biological activity of analogs of the antitumor drug cisplatin that contain chiral amine ligands. Interaction with DNA and formation of cross-links with adjacent purine bases are considered to be the crucial steps in the antitumor activity of this class of complexes. Because double-helical DNA has a chiral structure, interaction with enantiomeric complexes of platinum should lead to diastereomeric adducts. It has been demonstrated that DNA cross-links of platinum complexes with enantiomeric amine ligands not only can exhibit different conformational features but also can be processed differently by the cellular machinery as a consequence of these conformational differences. These results expand the general knowledge of how the stereochemistry of the platinum-DNA adduct can influence the cell response and contribute to understanding the processes that are crucial for antitumor activity. The steric requirements of the chiral ligands, in terms of configuration and flexibility, are also elucidated.

Full Text

The Full Text of this article is available as a PDF (148.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ano Susan O., Intini Francesco P., Natile Giovanni, Marzilli Luigi G. Retro Models of Pt Anticancer Drug DNA Adducts: Chirality-Controlling Chelate Ligand Restriction of Guanine Dynamic Motion in (2,2'-Bipiperidine)PtG(2) Complexes (G = Guanine Derivative). Inorg Chem. 1999 Jun 14;38(12):2989–2999. doi: 10.1021/ic981409g. [DOI] [PubMed] [Google Scholar]
  2. Barry M. A., Behnke C. A., Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol. 1990 Nov 15;40(10):2353–2362. doi: 10.1016/0006-2952(90)90733-2. [DOI] [PubMed] [Google Scholar]
  3. Barry M. A., Behnke C. A., Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol. 1990 Nov 15;40(10):2353–2362. doi: 10.1016/0006-2952(90)90733-2. [DOI] [PubMed] [Google Scholar]
  4. Boudný V., Vrána O., Gaucheron F., Kleinwachter V., Leng M., Brabec V. Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes. Nucleic Acids Res. 1992 Jan 25;20(2):267–272. doi: 10.1093/nar/20.2.267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Coluccia M., Fanizzi F. P., Giannini G., Giordano D., Intini F. P., Lacidogna G., Loseto F., Mariggio M. A., Nassi A., Natile G. Synthesis, mutagenicity, binding to pBR 322 DNA and antitumour activity of platinum(II) complexes with ethambutol. Anticancer Res. 1991 Jan-Feb;11(1):281–287. [PubMed] [Google Scholar]
  6. Eastman A. Interstrand cross-links and sequence specificity in the reaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry. 1985 Sep 10;24(19):5027–5032. doi: 10.1021/bi00340a011. [DOI] [PubMed] [Google Scholar]
  7. Fenton R. R., Easdale W. J., Er H. M., O'Mara S. M., McKeage M. J., Russell P. J., Hambley T. W. Preparation, DNA binding, and in vitro cytotoxicity of a pair of enantiomeric platinum(II) complexes, [(R)- and (S)-3-aminohexahydroazepine]dichloroplatinum(II). Crystal structure of the S enantiomer. J Med Chem. 1997 Mar 28;40(7):1090–1098. doi: 10.1021/jm9607966. [DOI] [PubMed] [Google Scholar]
  8. Fichtinger-Schepman A. M., van der Veer J. L., den Hartog J. H., Lohman P. H., Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry. 1985 Jan 29;24(3):707–713. doi: 10.1021/bi00324a025. [DOI] [PubMed] [Google Scholar]
  9. Kaspárková J., Brabec V. Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans isomer by DNA-binding proteins. Biochemistry. 1995 Sep 26;34(38):12379–12387. doi: 10.1021/bi00038a035. [DOI] [PubMed] [Google Scholar]
  10. Kidani Y., Inagaki K., Iigo M., Hoshi A., Kuretani K. Antitumor activity of 1,2-diaminocyclohexane--platinum complexes against sarcoma-180 ascites form. J Med Chem. 1978 Dec;21(12):1315–1318. doi: 10.1021/jm00210a029. [DOI] [PubMed] [Google Scholar]
  11. Kidani Y., Inagaki K., Tsukagoshi S. Examination of antitumor activities of platinum complexes of 1,2-diaminocyclohexane isomers and their related complexes. Gan. 1976 Dec;67(6):921–922. [PubMed] [Google Scholar]
  12. Kidani Y., Noji M., Tashiro T. Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers. Gan. 1980 Oct;71(5):637–643. [PubMed] [Google Scholar]
  13. Lemaire M. A., Schwartz A., Rahmouni A. R., Leng M. Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum (II) and DNA. Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1982–1985. doi: 10.1073/pnas.88.5.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Malina J., Hofr C., Maresca L., Natile G., Brabec V. DNA interactions of antitumor cisplatin analogs containing enantiomeric amine ligands. Biophys J. 2000 Apr;78(4):2008–2021. doi: 10.1016/S0006-3495(00)76748-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Malina Jaroslav, Kasparkova Jana, Natile Giovanni, Brabec Viktor. Recognition of major DNA adducts of enantiomeric cisplatin analogs by HMG box proteins and nucleotide excision repair of these adducts. Chem Biol. 2002 May;9(5):629–638. doi: 10.1016/s1074-5521(02)00134-5. [DOI] [PubMed] [Google Scholar]
  16. Misset J. L. Oxaliplatin in practice. Br J Cancer. 1998 Jun;77 (Suppl 4):4–7. doi: 10.1038/bjc.1998.428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Noji M., Gohchi Y., Kidani Y. Preparation of antitumor platinum(II) complexes of 1,2-diphenylethylenediamine isomers and their interactions with DNA and its purine moieties. Chem Biol Interact. 1984 Sep 1;51(1):37–48. doi: 10.1016/0009-2797(84)90018-8. [DOI] [PubMed] [Google Scholar]
  18. Noji M., Motoyama S., Tashiro T., Kidani Y. Synthesis and antitumor activity of Pt(II) complexes containing 2,3-diaminopropanol isomers. Chem Pharm Bull (Tokyo) 1983 May;31(5):1469–1473. doi: 10.1248/cpb.31.1469. [DOI] [PubMed] [Google Scholar]
  19. Noji M., Okamoto K., Kidani Y., Tashiro T. Relation of conformation to antitumor activity of platinum(II) complexes of 1,2-cyclohexanediamine and 2-(aminomethyl)cyclohexylamine isomers against leukemia P388. J Med Chem. 1981 May;24(5):508–515. doi: 10.1021/jm00137a007. [DOI] [PubMed] [Google Scholar]
  20. Ohndorf U. M., Rould M. A., He Q., Pabo C. O., Lippard S. J. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature. 1999 Jun 17;399(6737):708–712. doi: 10.1038/21460. [DOI] [PubMed] [Google Scholar]
  21. Okamoto K., Noji M., Tashiro T., Kidani Y. Preparation of platinum(II) complexes of diamine isomers [PtX(1,3-diamine)] (X = Cl2, SO4, (NO3)2, oxalato, D-glucuronato, and D-gluconato) and determination of their antitumor activity against leukemia L1210. Chem Pharm Bull (Tokyo) 1981 Apr;29(4):929–939. doi: 10.1248/cpb.29.929. [DOI] [PubMed] [Google Scholar]
  22. Ormerod M. G., O'Neill C., Robertson D., Kelland L. R., Harrap K. R. cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol. 1996;37(5):463–471. doi: 10.1007/s002800050413. [DOI] [PubMed] [Google Scholar]
  23. Reardon J. T., Vaisman A., Chaney S. G., Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res. 1999 Aug 15;59(16):3968–3971. [PubMed] [Google Scholar]
  24. Rice J. A., Crothers D. M., Pinto A. L., Lippard S. J. The major adduct of the antitumor drug cis-diamminedichloroplatinum(II) with DNA bends the duplex by approximately equal to 40 degrees toward the major groove. Proc Natl Acad Sci U S A. 1988 Jun;85(12):4158–4161. doi: 10.1073/pnas.85.12.4158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rixe O., Ortuzar W., Alvarez M., Parker R., Reed E., Paull K., Fojo T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol. 1996 Dec 24;52(12):1855–1865. doi: 10.1016/s0006-2952(97)81490-6. [DOI] [PubMed] [Google Scholar]
  26. Schröder Guy, Kozelka Jirí, Sabat Michal, Fouchet Marie-Hélène, Beyerle-Pfnür Rut, Lippert Bernhard. Model of the Second Most Abundant Cisplatin-DNA Cross-Link: X-ray Crystal Structure and Conformational Analysis of cis-[(NH(3))(2)Pt(9-MeA-N7)(9-EtGH-N7)](NO(3)).2H(2)O (9-MeA = 9-Methyladenine; 9-EtGH = 9-Ethylguanine). Inorg Chem. 1996 Mar 13;35(6):1647–1652. doi: 10.1021/ic950754s. [DOI] [PubMed] [Google Scholar]
  27. Sherman S. E., Gibson D., Wang A. H., Lippard S. J. X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2(d(pGpG))]. Science. 1985 Oct 25;230(4724):412–417. doi: 10.1126/science.4048939. [DOI] [PubMed] [Google Scholar]
  28. Sorenson C. M., Barry M. A., Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst. 1990 May 2;82(9):749–755. doi: 10.1093/jnci/82.9.749. [DOI] [PubMed] [Google Scholar]
  29. Spingler B., Whittington D. A., Lippard S. J. 2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex. Inorg Chem. 2001 Oct 22;40(22):5596–5602. doi: 10.1021/ic010790t. [DOI] [PubMed] [Google Scholar]
  30. Takahara P. M., Rosenzweig A. C., Frederick C. A., Lippard S. J. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature. 1995 Oct 19;377(6550):649–652. doi: 10.1038/377649a0. [DOI] [PubMed] [Google Scholar]
  31. Vickery K., Bonin A. M., Fenton R. R., O'Mara S., Russell P. J., Webster L. K., Hambley T. W. Preparation, characterization, cytotoxicity, and mutagenicity of a pair of enantiomeric platinum(II) complexes with the potential to bind enantioselectively to DNA. J Med Chem. 1993 Nov 12;36(23):3663–3668. doi: 10.1021/jm00075a022. [DOI] [PubMed] [Google Scholar]
  32. Wei M., Cohen S. M., Silverman A. P., Lippard S. J. Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins. J Biol Chem. 2001 Aug 20;276(42):38774–38780. doi: 10.1074/jbc.M106374200. [DOI] [PubMed] [Google Scholar]
  33. Zamble D. B., Mu D., Reardon J. T., Sancar A., Lippard S. J. Repair of cisplatin--DNA adducts by the mammalian excision nuclease. Biochemistry. 1996 Aug 6;35(31):10004–10013. doi: 10.1021/bi960453+. [DOI] [PubMed] [Google Scholar]
  34. Zlatanova J., Yaneva J., Leuba S. H. Proteins that specifically recognize cisplatin-damaged DNA: a clue to anticancer activity of cisplatin. FASEB J. 1998 Jul;12(10):791–799. doi: 10.1096/fasebj.12.10.791. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES